PC
GILD icon

Parrish Capital’s Gilead Sciences GILD Stock Holding History

Parrish Capital’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.47M Sell
19,540
-3,206
-14% -$422K 2.38% 7
2026
Q1 		$3.17M Sell
22,746
-1,149
-5% -$161K 2.83% 3
2025
Q4 		$2.93M Buy
+23,895
New +$2.9M 2.66% 5

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Parrish Capital's GILD Position: Q2 2026 in Review

Parrish Capital reduced its Gilead Sciences (GILD) stake by 14% in Q2 2026, selling an estimated $422K and leaving 19,540 shares worth $2.47M. The position accounts for 2.38% of the portfolio, ranked #7.

Parrish Capital first reported a position in GILD in Q4 2025 and has held it in 3 quarters since. The position peaked at $3.17M in Q1 2026. 2,284 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Parrish Capital held 19,540 shares of Gilead Sciences worth $2.47M as of Q2 2026.
  • Parrish Capital sold 3,206 Gilead Sciences shares in Q2 2026, an estimated $422K.
  • Gilead Sciences made up 2.38% of Parrish Capital's portfolio in Q2 2026, its #7 holding.
  • Parrish Capital first reported a position in Gilead Sciences in Q4 2025 and has held it in 3 quarters since.
  • Parrish Capital's Gilead Sciences position peaked at $3.17M in Q1 2026.
  • 2,284 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Parrish Capital's 13F filing for Q2 2026, filed 1 Sep 2026.